A performance analysis of the current constituents of the S&P 500 Index Over the Last 30 Years ending September 2024 ...

It doesn’t stop people from getting worse ... that FDA's approval of a similar Alzheimer's drug called Aduhelm — also from Biogen and Eisai — was “rife with irregularities,” including ...

Lilly maintains that the potential to stop ... of Aduhelm’s rollout - marred by controversy over its efficacy data - Leqembi started slowly, but has shown signs of picking up. Biogen said ...

A panel discussing neurodegeneration reflected on the recent progress in Alzheimer’s following the controversial FDA approval and then discontinuation of Biogen’s Aduhelm (aducanumab), followe ...

In a rare – and possibly unique – turn of events, both pharmacy company Biogen and its shareholders have asked a federal ...

with management confident in overcoming any major hurdles based on their experience from the Aduhelm launch. Furthermore, Biogen’s proactive approach to building out infrastructure to support ...

Shares of Biogen Inc. BIIB inched 0.49% higher to $185.68 Friday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.90% to 5,751.07 and ...

In this article, we are going to take a look at where Biogen Inc. (NASDAQ:BIIB) stands against the other bargain stocks. September has historically been sluggish for stocks. However, with an ...